[go: up one dir, main page]

WO2013045607A1 - Dérivés tricycliques hétéroaromatiques liés à de la quinazoline pouvant être utilisés en tant qu'inhibiteurs de l'enzyme pde10a - Google Patents

Dérivés tricycliques hétéroaromatiques liés à de la quinazoline pouvant être utilisés en tant qu'inhibiteurs de l'enzyme pde10a Download PDF

Info

Publication number
WO2013045607A1
WO2013045607A1 PCT/EP2012/069179 EP2012069179W WO2013045607A1 WO 2013045607 A1 WO2013045607 A1 WO 2013045607A1 EP 2012069179 W EP2012069179 W EP 2012069179W WO 2013045607 A1 WO2013045607 A1 WO 2013045607A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluoro
imidazo
quinazolin
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/069179
Other languages
English (en)
Inventor
Mauro Marigo
John Paul Kilburn
Jacob Nielsen
Ask Püschl
Morten LANGGÅRD
Mikkel JESSING
Jan Kehler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of WO2013045607A1 publication Critical patent/WO2013045607A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention provides heteroaromatic compounds that are PDE10A enzyme inhibitors, and as such are useful to treat neurodegenerative and psychiatric disorders. Especially, the invention provides compounds that are highly selective for PDE10 over other PDE subtypes. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
  • cyclic-adenosine monophosphate cyclic-adenosine monophosphate
  • cGMP cyclic- guanosine monophosphate
  • Intracellular cAMP and cGMP are generated by adenyl and guanyl cyclases, and are degraded by cyclic nucleotide phosphodiesterases (PDEs) via hydrolysis of the cyclic nucleotides into their respective nucleotide monophosphates.
  • PDEs cyclic nucleotide phosphodiesterases
  • Phosphodieasterase 10A is a dual-specificity phosphodiesterase that can convert both cAMP to AMP and cGMP to GMP (Soderling, S. et al. Proc. Natl. Acad. Sci. 1999, 96, 7071 -7076). PDE10A is primarily expressed in the neurons in the striatum, n. accumbens and in the olfactory tubercle (Kotera, J. et al. Biochem. Biophys. Res. Comm. 1999, 261, 551 -557 and Seeger, T.F. et al. Brain Research, 2003, 985, 1 13-126).
  • MSN medium spiny neurons
  • D 2 D 2 dopamine receptors
  • the Di class of neurons is part of the 'direct' striatal output pathway, which broadly functions to facilitate behavioral responses.
  • the D 2 class of neurons is part of the 'indirect' striatal output pathway, which functions to suppress behavioral responses that compete with those being facilitated by the 'direct' pathway.
  • Dopamine D 2 receptor antagonism is well established in the treatment of schizophrenia.
  • D 2 receptor antagonism has been the mainstay in psychosis treatment and all effective antipsychotic drugs antagonise D 2 receptors.
  • the effects of D 2 are likely to be mediated primarily through neurons in the striatum, nucleus accumbens and olfactory tubercle, since these areas receive the densest dopaminergic projections and have the strongest expression of D 2 receptors (Konradi, C. and Heckers, S. Society of Biological Psychiatry, 2001 , 50, 729-742).
  • PDE10A in this context, has the desired expression profile with high and relatively specific expression in neurons in striatum, nucleus accumbens and olfactory tubercle, PDE10A inhibition is likely to have effects similar to D 2 receptor antagonism and therefore have antipsychotic effects.
  • PDE10A inhibition is expected to mimic D 2 receptor antagonism in part, it might be expected to have a different profile.
  • the D 2 receptor has signaling components besides cAMP (Neve, K. A. et al. Journal of Receptors and Signal Transduction 2004, 24, 165-205), wherefore interference with cAMP through PDE10A inhibition may reduce the risk of the extrapyramidal side effects that are seen with strong D 2 antagonism.
  • PDE10A inhibition may have some effects not seen with D 2 receptor antagonism.
  • PDE10A is also expressed in Di receptors expressing striatal neurons (Seeger, T. F. et al. Brain Research, 2003, 985, 1 13-126).
  • PDE10A inhibition is likely to also have effects that mimic Di receptor agonism.
  • PDE10A inhibition will not only increase cAMP in cells, but might also be expected to increase cGMP levels, since PDE10A is a dual specificity phosphodiesterase.
  • cGMP activates a number of target protein in cells like cAMP and also interacts with the cAMP signaling pathways.
  • PDE10A inhibition is likely to mimic D 2 receptor antagonism in part and therefore has antipsychotic effect, but the profile might differ from that observed with classical D 2 receptor antagonists.
  • the PDE10A inhibitor papaverine is shown to be active in several antipsychotic models. Papaverine potentiated the cataleptic effect of the D 2 receptor antagonist haloperidol in rats, but did not cause catalepsy on its own (WO 03/093499). Papaverine reduced hyperactivity in rats induced by PCP, while reduction of amphetamine induced hyperactivity was insignificant (WO 03/093499). These models suggest that PDE10A inhibition has the classic antipsychotic potential that would be expected from the theoretical considerations outlined above. WO 03/093499 further discloses the use of selective PDE10 inhibitors for the treatment of associated neurologic and psychiatric disorders.
  • PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats (Rodefer et al. Eur. J. Neurosci. 2005, 4, 1070-1076). This model suggests that PDE10A inhibition might alleviate cognitive deficits associated with schizophrenia.
  • the tissue distribution of PDE10A indicates that PDE10A inhibitors can be used to raise levels of cAMP and/or cGMP within cells that express the PDE10A enzyme, especially neurons that comprise the basal ganglia, and the PDE10A inhibitors of the present invention would therefore be useful in treating a variety of associated neuropsychiatric conditions involving the basal ganglia such as neurological and psychiatric disorders, schizophrenia, bipolar disorder, psychosis, obsessive compulsive disorder and addiction, and may have the benefit of not possessing unwanted side effects, which are associated with the current therapies on the market.
  • Pyrrolodihydroisoquinolines and variants thereof are disclosed as inhibitors of PDE10 in WO 05/03129 and WO 05/02579.
  • Piperidinyl-substituted quinazolines and isoquinolines that serve as PDE10 inhibitors are disclosed in WO 05/82883.
  • WO 06/1 1040 discloses substituted quinazoline and isoquinoline compounds that serve as inhibitors of PDE10.
  • US 20050182079 discloses substituted tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline that serve as effective phosphodiesterase (PDE) inhibitors.
  • PDE phosphodiesterase
  • US 20060019975 discloses piperidine derivatives of quinazoline and isoquinoline that serve as effective phosphodiesterase (PDE) inhibitors.
  • US 20060019975 also relates to compounds that are selective inhibitors of PDE10.
  • WO 06/028957 discloses cinnoline derivatives as inhibitors of PDE10 for the treatment of psychiatric and neurological syndromes.
  • WO09/152825 discloses phenylimidazole derivatives as compounds that serve as inhibitors of PDE10.
  • the present invention provides compounds that are PDE10A enzyme inhibitors and thus useful for treatment for neurodegenerative and/or psychiatric disorders, which are not efficacious in all patients. Hence, there remains a need for alternative methods of treatment. Summary of the Invention
  • the objective of the present invention is to provide compounds that are selective PDE10A enzyme inhibitors.
  • a further objective of the present invention is to provide compounds which have such activity, and which have improved solubility, metabolic stability and/or bioavailability compared to prior art compounds.
  • Another objective of the invention is to provide an effective treatment, in particular long-term treatment, of a human patient, without causing the side effects typically associated with current therapies for neurological and psychiatric disorders.
  • Embodiments of the invention in a first embodiment (E1 ) the present invention relates to compounds of formula I:
  • R6, R7, R8, R9, R10, R1 1 and R12 are individually selected from the group consisting of hydrogen, halogen, Ci-C6 alkyl and Ci-C 4 alkoxy, and wherein * denotes the attachment point, and tautomers and pharmaceutically acceptable salts thereof, and polymorphic forms thereof.
  • R1 is selected from the group consisting of hydrogen, methyl, methoxy, methylamine and triflourmethyl.
  • R2, R3, R4 and R5 are selected from the group consisting of fluorine and bromine.
  • R6, R7, R8, R9, R10, R1 1 and R12 are individually selected from the group consisting of hydrogen, fluorine and methoxy.
  • the invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, for use as a medicament.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I and a pharmaceutically acceptable carrier, diluent or excipient.
  • the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a neurodegenerative or psychiatric disorder.
  • the present invention provides a method of treating a subject suffering from a neurodegenerative disorder, comprising administering to the subject a therapeutically effective amount of a compound of formula I.
  • the present invention provides a method of treating a subject suffering from a psychiatric disorder, comprising administering to the subject a therapeutically effective amount of a compound of formula I.
  • the present invention provides a method of treating a subject suffering from a drug addiction, such as an alcohol, amphetamine, cocaine, or opiate addiction.
  • a drug addiction such as an alcohol, amphetamine, cocaine, or opiate addiction.
  • halo and halogen are used interchangeably and refer to fluorine, chlorine, bromine or iodine.
  • C1 -C6 alkyl refers to a straight-chain or branched saturated hydrocarbon having from one to six carbon atoms, inclusive. Examples of such groups include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, 1 - butyl, 2-butyl, 2-methyl-2-propyl, 2-methyl-1 -butyl, and n-hexyl.
  • C1 -C6 hydroxyalkyl refers to a C1 -C6 alkyl group as defined above which is substituted with one hydroxy group.
  • halo(Ci - C6)alkyl refers to a C1 -C6 alkyl group as defined above which is substituted with up to three halogen atoms, such as trifluoromethyl.
  • C1 -C6 alkoxy refers to a straight-chain or branched saturated alkoxy group having from one to six carbon atoms, inclusive, with the open valency on the oxygen. Examples of such groups include, but are not limited to, methoxy, ethoxy, n-butoxy, 2-methyl-pentoxy and n-hexyloxy.
  • C3-C8 cycloalkyi typically refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl.
  • C1 -C6 alkyl(C3-C8)cycloalkyl refers to a C3-C8 cycloalkyi as defined above which is substituted with a straight-chain or branched C1-C6 alkyl. Examples of such groups include, but are not limited to, cyclopropylmethyl.
  • heterocycloalkyl refers to a four to eight membered ring containing carbon atoms and up to three N, O or S atoms, provided that the four to eight membered ring does not contain adjacent O or adjacent S atoms.
  • the open valency is on either the heteroatom or carbon atom. Examples of such groups include, but are not limited to, azetidinyl, oxetanyl, piperazinyl, morpholinyl, thiomorpholinyl and [1 ,4]diazepanyl.
  • hydroxyheterocycloalkyl refers to a heterocycloalkyl as defined above which is substituted with one hydroxy group.
  • C1-C6 alkyl-heterocycloalkyl refers to a heterocycloalkyl as defined above which is substituted with a C1-C6 alkyl group.
  • Examples of such groups include, but are not limited to, tetrahydropyran-4-yl-methyl and 2-morpholin-4-yl-ethyl.
  • aryl refers to a phenyl ring, optionally substituted with halogen, Ci- C6 alkyl, C1-C6 alkoxy or halo(Ci-Ce)alkyl as defined above. Examples of such groups include, but are not limited to, phenyl and 4-chlorophenyl.
  • d-Cearylalkyl refers to an aryl as defined above which is substituted with a straight-chain or branched C1-C6 alkyl. Examples of such groups include, but are not limited to, benzyl and 4-chlorobenzyl.
  • the present invention further provides certain embodiments of the invention that are described below.
  • HET is a heteroaromatic group of formula II containing 2 nitrogen atoms. In another embodiment of the invention, HET is a heteroaromatic group of formula II containing 3 nitrogen atoms. In yet another embodiment of the invention, HET is a heteroaromatic group of formula II containing 4 nitrogen atoms. In a further embodiment one or more of the hydrogen atoms of the compound of formula I have been substituted by deuterium.
  • the compound of formula I is selected among the following specific compounds listed in Table 1 and Table2, in the form of the free base, one or more tautomers thereof or a pharmaceutically acceptable salt thereof.
  • Table 1 lists compounds of the invention where HET is a 2-quinazolinyl group of formula I la and the corresponding IC 5 o values determined as described in the section "PDE10A inhibition assay”.
  • Table 2 lists compounds of the invention where HET is a 4- quinazolinyl group of formula Mb and the corresponding IC 5 o values determined as described in the section "PDE10A inhibition assay".
  • Each of the compounds constitutes an individual embodiment, of the present invention. It should be understood that the various aspects, embodiments, implementations and features of the invention mentioned herein may be claimed separately, or in any combination, as illustrated by the following non- limiting examples.
  • the compounds of the present invention have an IC 5 o value of less than 50 nM, such as in the range of 0.2 - 20 nM, particularly in the range of 0.2 - 10 nM, such as in the range of 0.2 - 5 nM or in the range of 0.2 - 1 nM.
  • the present invention also comprises salts of the compounds, typically, pharmaceutically acceptable salts.
  • Such salts include pharmaceutically acceptable acid addition salts.
  • Acid addition salts include salts of inorganic acids as well as organic acids.
  • suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like.
  • suitable organic acids include formic, acetic, trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic, benzenesulfonic, p-tol
  • the compounds of this invention may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purposes of this invention.
  • the present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I and a pharmaceutically acceptable carrier or diluent.
  • the present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of one of the specific compounds disclosed in the Experimental Section herein and a pharmaceutically acceptable carrier or diluent.
  • the compounds of the invention may be administered alone or in combination with pharmaceutically acceptable carriers, diluents or excipients, in either single or multiple doses.
  • pharmaceutical compositions according to the invention may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 19 th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995.
  • compositions may be specifically formulated for administration by any suitable route such as oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), transdermal, intracisternal, intraperitoneal, vaginal and parenteral (including subcutaneous, intramuscular, intrathecal, intravenous and intradermal) routes. It will be appreciated that the route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated and the active ingredient.
  • compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders and granules. Where appropriate, the compositions may be prepared with coatings such as enteric coatings or they may be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.
  • Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups and elixirs.
  • Pharmaceutical compositions for parenteral administration include sterile aqueous and nonaqueous injectable solutions, dispersions, suspensions or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
  • Other suitable administration forms include, but are not limited to, suppositories, sprays, ointments, creams, gels, inhalants, dermal patches and implants.
  • Typical oral dosages range from about 0.001 to about 100 mg/kg body weight per day. Typical oral dosages also range from about 0.01 to about 50 mg/kg body weight per day. Typical oral dosages further range from about 0.05 to about 10 mg/kg body weight per day. Oral dosages are usually administered in one or more dosages, typically, one to three dosages per day. The exact dosage will depend upon the frequency and mode of administration, the sex, age, weight and general condition of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
  • a typical unit dosage form for oral administration may contain from about 0.01 to about 1000 mg, from about 0.05 to about 500 mg, or from about 0.5 mg to about 200 mg.
  • parenteral routes such as intravenous, intrathecal, intramuscular and similar administration
  • typical doses are in the order of half the dose employed for oral administration.
  • the present invention also provides a process for making a pharmaceutical composition
  • a pharmaceutical composition comprising admixing a therapeutically effective amount of a compound of formula I and at least one pharmaceutically acceptable carrier or diluent.
  • the compound utilized in the aforementioned process is one of the specific compounds disclosed in the Experimental Section herein.
  • the compounds of this invention are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
  • One example is an acid addition salt of a compound having the utility of a free base.
  • a compound of formula I contains a free base such salts are prepared in a conventional manner by treating a solution or suspension of a free base of formula I with a molar equivalent of a pharmaceutically acceptable acid.
  • suitable organic and inorganic acids are described above.
  • solutions of the compounds of formula I in sterile aqueous solution, aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed.
  • aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
  • the compounds of formula I may be readily incorporated into known sterile aqueous media using standard techniques known to those skilled in the art.
  • Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
  • solid carriers include lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
  • liquid carriers include, but are not limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water.
  • the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the pharmaceutical compositions formed by combining the compounds of formula I and a pharmaceutically acceptable carrier are then readily administered in a variety of dosage forms suitable for the disclosed routes of administration.
  • the formulations may conveniently be presented in unit dosage form by methods known in the art of pharmacy.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and optionally a suitable excipient.
  • the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
  • the preparation may be tabletted, placed in a hard gelatin capsule in powder or pellet form or it may be in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but will range from about 25 mg to about 1 g per dosage unit.
  • the preparation may be in the form of a syrup, emulsion, soft gelatin capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
  • compositions of the invention may be prepared by conventional methods in the art.
  • tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tabletting machine prepare tablets.
  • adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatin, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colorings, flavorings, preservatives etc. may be used provided that they are compatible with the active ingredients.
  • the term "therapeutically effective amount" of a compound means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications in a therapeutic intervention comprising the administration of said compound.
  • An amount adequate to accomplish this is defined as “therapeutically effective amount”.
  • Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician.
  • treatment means the management and care of a patient for the purpose of combating a condition, such as a disease or a disorder.
  • the term is intended to include the full spectrum of treatments for a given condition from which the patient is suffering, such as administration of the active compound to alleviate the symptoms or complications, to delay the progression of the disease, disorder or condition, to alleviate or relief the symptoms and complications, and/or to cure or eliminate the disease, disorder or condition as well as to prevent the condition, wherein prevention is to be understood as the management and care of a patient for the purpose of combating the disease, condition, or disorder and includes the administration of the active compounds to prevent the onset of the symptoms or complications. Nonetheless, prophylactic (preventive) and therapeutic (curative) treatments are two separate aspects of the invention.
  • the patient to be treated is preferably a mammal, in particular a human being.
  • the compounds of formula I are PDE10A enzyme inhibitors and as such are useful to treat associated neurological and psychiatric disorders.
  • the invention thus provides a compound of formula I or a pharmaceutically acceptable acid addition salt thereof, as well as a pharmaceutical composition containing such a compound, for use in the treatment of a neurodegenerative disorder, psychiatric disorder or drug addiction in humans.
  • the neurodegenerative disorder or condition involves neurodegeneration of striatal medium spiny neurons in a human.
  • the neurodegenerative disorder or condition is Huntington's disease.
  • the disorder is dyskinesia associated with dopamine agonist therapy.
  • the psychiatric disorder is selected from the group consisting of schizophrenia, for example of the paranoid, disorganized, catatonic, undifferentiated, or residual type; schizophreniform disorder; schizoaffective disorder, for example of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine; personality disorder of the paranoid type; and personality disorder of the schizoid type.
  • schizophrenia for example of the paranoid, disorganized, catatonic, undifferentiated, or residual type
  • schizophreniform disorder for example of the delusional type or the depressive type
  • delusional disorder substance-induced psychotic disorder, for example psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyclidine
  • personality disorder of the paranoid type and personality
  • This invention further provides a method of treating a drug addiction, for example an alcohol, amphetamine, cocaine, or opiate addiction, in a human, which method comprises administering to said human an amount of a compound of formula I effective in treating addiction, such as drug addiction.
  • a drug addiction for example an alcohol, amphetamine, cocaine, or opiate addiction
  • drug addiction means an abnormal desire for a drug and is generally characterized by motivational disturbances such a compulsion to take the desired drug and episodes of intense drug craving.
  • Other disorders that can be treated according to the present invention are obsessive/compulsive disorders, non-insuline demanding diabetes mellitus (NIDDM), and Tourette's syndrome and other tic disorders as well as Attention Deficit/Hyperactivity Disorder (ADHD).
  • NIDDM non-insuline demanding diabetes mellitus
  • ADHD Attention Deficit/Hyperactivity Disorder
  • the compounds of formula I or pharmaceutically acceptable salts thereof may be used in combination with one or more other drugs (including typical and atypical antpsychotic agent) in the treatment of diseases or conditions for which the compounds of the present invention have utility, where the combination of the drugs together are safer or more effective than either drug alone.
  • the compounds of the present invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the present invention.
  • the combinations, uses and methods of treatment of the invention may also provide advantages in treatment of patients who fail to respond adequately or who are resistant to other known treatments.
  • compositions of the present invention include those that contain one or more other active ingredients, in addition to the compounds of the present invention.
  • the combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.
  • neuroleptic agent refers to drugs, which have the effect on cognition and behaviour of antipsychotic agent drugs that reduce confusion, delusions, hallucinations, and psychomotor agitation in patients with psychoses.
  • neuroleptic agents include, but are not limited to: typical antipsychotic drugs, including phenothiazines, further divided into the aliphatics, piperidines, and piperazines, thioxanthenes (e.g., cisordinol), butyrophenones (e.g., haloperidol), dibenzoxazepines (e.g., loxapine), dihydroindolones (e.g., molindone), diphenylbutylpiperidines (e.g., pimozide), and atypical antipsychotic drugs, including benzisoxazoles (e.g., risperidone), sertindole, olan
  • neuroleptic agents for use in the invention are sertindole, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone and osanetant.
  • a "neurodegenerative disorder or condition” refers to a disorder or condition that is caused by the dysfunction and/or death of neurons in the central nervous system.
  • the treatment of these disorders and conditions can be facilitated by administration of an agent which prevents the dysfunction or death of neurons at risk in these disorders or conditions and/or enhances the function of damaged or healthy neurons in such a way as to compensate for the loss of function caused by the dysfunction or death of at-risk neurons.
  • neurotrophic agent refers to a substance or agent that has some or all of these properties.
  • LC-MS were run on a Sciex API150EX equipped with APPI-source operating in positive ion mode.
  • the HPLC consisted of Shimadzu LC10-ADvp LC pumps. SPD-M20A PDA detector (operating at 254 nM) and SCL-10A system controller. Autosampler was Gilson 215. Colomn oven was a Jones Chromatography 7990R and ELS detector was a Sedere Sedex 85.
  • LC-conditions The column was a Waters Symmetry C-18. 4.6 x 30 mm. 3.5 ⁇ operating at 60 °C with 2.5 ml/min of a binary gradient consisting of water + 0.05 % TFA (A) and methanol + 0.05 % TFA. Gradient:
  • LC-MS were run on a Sciex API300 equipped with APPI source operating in positive ion mode.
  • the UPLC consisted of Waters Aquity including column mager. binary solvent manager, sample organizer. PDA detector (operating at 254 nM) and ELS detector.
  • LC-conditions The column was a Waters Aquity UPLC BEH C-18. 2.1 x 50 mm. 1 .7 ⁇ operating at 60 °C with 1 .2 ml/min of a binary gradient consisting of water + 0.05 % TFA (A) and 95 % acetonitrile containing 5 % water + 0.03 % TFA. Gradient Time. min. %B
  • LC-MS were run on an Agilent 1 100 LCMS system with ELS Detector, Pump G131 1A, Degasser G1379A,Well-plate Autosampler, G1367A, Column Oven G1316A, DAD G1315B,MSD G1946C or G1956A,Alltech ELSD 800,Column YMC ODS-AQ,Particle size 5 micrometer, Pore size 12 nm, Dimension 50 * 2.0 mm ID, Injection volume 2 microliter, Column temperature 50°C, Flow 0.8 ml/min.
  • This reaction is typically carried out in a solvent such as 1 -propanol, toluene, DMF, or acetonitrile, optionally in the presence of a carbonate base such as potassium carbonate or a tertiary amine base such as triethylamine or diisopropylethylannine (DIPEA), at a temperature ranging from about 0°C to about 200°C, optionally under pressure in a closed vessel.
  • a solvent such as 1 -propanol, toluene, DMF, or acetonitrile
  • a carbonate base such as potassium carbonate
  • a tertiary amine base such as triethylamine or diisopropylethylannine (DIPEA)
  • DIPEA diisopropylethylannine
  • suitable solvents include benzene, chloroform, dioxane, ethyl acetate, 2-propanol and xy
  • Thiol-compounds of formula IV are either commercially available or can be made by methods similar to those described in the literature e.g. Journal of Heterocyclic Chemistry 1977 14(5), 889-92, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry 1979, 5, 1 132-6, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio- Organic Chemistry 1997, 20, 2983-2988, Organic & Biomolecular Chemistry 2009, 7, 128-134.
  • Electrophiles of formula III can be prepared as described in e.g. Venkatesan, A. et al. ChemMedChem 2008, 3, 1658-1661 .
  • a transition metal catalyst such as palladium metal
  • a hydrogen source such as hydrogen gas, ammonium hydrogen carbonate, or cyclohexadiene.
  • the reduction can be performed using tosylhydrazide TsNHNH2 in dimethylformamide at elevated temperature e.g. 130 °C.
  • Phosphonium salt of formula VII are readily available by reaction of compounds of formula V with triphenylphosphine by methods known to chemists skilled in the art.
  • Aldehydes of formula VIII are available by methods described in the literature se e.g. Venkatesan, A. et al.
  • This reaction is typically carried out in a suitable solvent, such as methanol and performed by mixing a solution of orthoacyl-anilide of formula XI in 7M NH3/MeOH solution and heating at 50°C for 6-24h.
  • a suitable solvent such as methanol
  • the orthoacyl-anilide of formula XI can be prepared from commercially available substituted anthranilic acids XII by standard organic synthesis methods known in the art as shown in scheme 5.
  • Active PDE10A enzyme is prepared in a number of ways for use in PDE assays (Loughney, K. et al. Gene 1999, 234, 109-1 17; Fujishige, K. et al. Eur J Biochem. 1999, 266, 1 1 18-1 127 and Soderling, S. et al. Proc. Natl. Acad. Sci. 1999, 96, 7071 -7076).
  • PDE10A can be expressed as full-length proteins or as truncated proteins, as long as they express the catalytic domain.
  • PDE10A can be prepared in different cell types, for example insect cells or E. coli.
  • catalytically active PDE10A is as follows: The catalytic domain of human PDE10A (amino acids 440-779 from the sequence with accession number NP 006652) is amplified from total human brain total RNA by standard RT-PCR and is cloned into the BamH1 and Xho1 sites of the pET28a vector (Novagen). Expression in coli is performed according to standard protocols. Briefly, the expression plasmids are transformed into the BL21 (DE3) E. coli strain, and 50 ml_ cultures inoculated with the cells allowed to grow to an OD600 of 0.4-0.6 before protein expression is induced with 0.5mM IPTG.
  • a PDE1 OA assay may for example, be performed as follows: The assay is performed in 60 uL samples containing a fixed amount of the relevant PDE enzyme (sufficient to convert 20-25% of the cyclic nucleotide substrate), a buffer (50 mM HEPES7.6; 10mM MgCI 2 ; 0.02% Tween20), 0.1 mg/ml BSA, 225 pCi of 3 H-labelled cyclic nucleotide substrate, tritium labeled cAMP to a final concentration of 5 nM and varying amounts of inhibitors.
  • Reactions are initiated by addition of the cyclic nucleotide substrate, and reactions are allowed to proceed for one hr at room temperature before being terminated through mixing with 15 uL 8 mg/mL yttrium silicate SPA beads (Amersham). The beads are allowed to settle for one hr in the dark before the plates are counted in a Wallac 1450 Microbeta counter. The measured signal can be converted to activity relative to an uninhibited control (100 %) and IC 5 o values can be calculated using the Xlfit extension to EXCEL.
  • mice Male mice (NMRI, Charles River) weighing 20-25g are used. Eight mice are used in each group receiving the test compound (5 mg/kg) plus PCP (2.3 mg/kg) including the parallel control groups receiving the vehicle of the test compound plus PCP or vehicle injections only. The injection volumen is 10 ml/kg. The experiment is made in normal light conditions in an undisturbed room. The test substance is injected per oss 60 min before injection of PCP, which is administered subcutaneous.
  • mice Immediately after injection of PCP the mice are placed individually in special designed test cage (20 cm x 32 cm). The activity is measured by 5X8 infrared light sources and photocells spaced by 4 cm. The light beams cross the cage 1 .8 cm above the bottom of the cage. Recording of a motility count requires interruption of adjacent light beams, thus avoiding counts induced by stationary movements of the mice.
  • Motility is recorded in 5 min intervals for a period of 1 hour.
  • the drug effect is calculated on the total counts during the 1 hour behavioral test period in the following manner:
  • the mean motility induced by vehicle treatment in the absence of PCP is used as baseline.
  • the 100 per cent effect of PCP is accordingly calculated to be total motility counts minus baseline.
  • the response in groups receiving test compound is thus determined by the total motility counts minus baseline, expressed in per cent of the similar result recorded in the parallel PCP control group.
  • the per cent responses are converted to per cent inhibition.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés de formule I qui sont des inhibiteurs de l'enzyme PDE10A, des compositions pharmaceutiques contenant une quantité thérapeutiquement efficace d'un composé de l'invention et un excipient pharmaceutiquement acceptable, et des procédés de préparation desdits composés de formule I. La présente invention concerne, en outre, une méthode de traitement d'un sujet souffrant d'une affection neurodégénérative, d'une toxicomanie ou d'un trouble psychiatrique, ladite méthode de traitement impliquant l'administration audit sujet d'une quantité thérapeutiquement efficace d'un composé de formule I. Dans la formule I, Q est choisi dans le groupe constitué de (Q1), (Q2), (Q3), (Q4) et (Q5).
PCT/EP2012/069179 2011-09-30 2012-09-28 Dérivés tricycliques hétéroaromatiques liés à de la quinazoline pouvant être utilisés en tant qu'inhibiteurs de l'enzyme pde10a Ceased WO2013045607A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161541113P 2011-09-30 2011-09-30
US61/541,113 2011-09-30
DKPA201100750 2011-09-30
DKPA201100750 2011-09-30

Publications (1)

Publication Number Publication Date
WO2013045607A1 true WO2013045607A1 (fr) 2013-04-04

Family

ID=47994312

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/069179 Ceased WO2013045607A1 (fr) 2011-09-30 2012-09-28 Dérivés tricycliques hétéroaromatiques liés à de la quinazoline pouvant être utilisés en tant qu'inhibiteurs de l'enzyme pde10a

Country Status (1)

Country Link
WO (1) WO2013045607A1 (fr)

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093499A2 (fr) 2002-05-03 2003-11-13 Pfizer Products Inc. Utilisation therapeutique d'inhibiteurs selectifs de pde10
WO2005002579A1 (fr) 2003-06-30 2005-01-13 Altana Pharma Ag Derives de pyrrolo-dihydroisoquinoline comme inhibiteurs de pde10
WO2005003129A1 (fr) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines comme inhibiteurs de pde10
WO2005012485A2 (fr) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
US20050182079A1 (en) 2004-02-18 2005-08-18 Pfizer Inc Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
WO2005120514A1 (fr) 2004-06-07 2005-12-22 Pfizer Products Inc. Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
WO2006028957A1 (fr) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation Derives de 4, 6-dialkoxy-cinnoline substitues en position 4 en tant qu'inhibiteurs de phospodiesterase 10 pour le traitement de syndromes psychiatriques ou neurologiques
WO2006072828A2 (fr) * 2005-01-07 2006-07-13 Pfizer Products Inc. Composes de quinoline heteroaromatiques
WO2008001182A1 (fr) * 2006-06-26 2008-01-03 Pfizer Products Inc. Composés hétéroaryliques tricycliques comme inhibiteurs de pde10
WO2009152825A1 (fr) 2008-06-20 2009-12-23 H. Lundbeck A/S Nouveau dérivés de phénylimidazole convenant comme inhibiteurs de l'enzyme pde10a
WO2010030027A1 (fr) * 2008-09-10 2010-03-18 Mitsubishi Tanabe Pharma Corporation Composés cycliques aromatiques azotés à 6 chaînons et leur utilisation
WO2012065612A1 (fr) * 2010-11-19 2012-05-24 H. Lundbeck A/S Dérivé d'imidazole en tant qu'inhibiteurs de l'enzyme pde10a

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093499A2 (fr) 2002-05-03 2003-11-13 Pfizer Products Inc. Utilisation therapeutique d'inhibiteurs selectifs de pde10
WO2005002579A1 (fr) 2003-06-30 2005-01-13 Altana Pharma Ag Derives de pyrrolo-dihydroisoquinoline comme inhibiteurs de pde10
WO2005003129A1 (fr) 2003-06-30 2005-01-13 Altana Pharma Ag Pyrrolodihydroisoquinolines comme inhibiteurs de pde10
WO2005012485A2 (fr) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
US20050182079A1 (en) 2004-02-18 2005-08-18 Pfizer Inc Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline
WO2005082883A2 (fr) 2004-02-18 2005-09-09 Pfizer Products Inc. Derives tetrahydroisoquinolinyliques de quinazoline et d'isoquinoline
WO2005120514A1 (fr) 2004-06-07 2005-12-22 Pfizer Products Inc. Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
WO2006011040A1 (fr) 2004-07-23 2006-02-02 Pfizer Products Inc. Derives quinazolin-4-yl- piperidine et cinnolin-4-yl-piperidine utilises en tant qu'inhibiteurs de pde10 pour le traitement de troubles du snc
WO2006028957A1 (fr) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation Derives de 4, 6-dialkoxy-cinnoline substitues en position 4 en tant qu'inhibiteurs de phospodiesterase 10 pour le traitement de syndromes psychiatriques ou neurologiques
WO2006072828A2 (fr) * 2005-01-07 2006-07-13 Pfizer Products Inc. Composes de quinoline heteroaromatiques
WO2008001182A1 (fr) * 2006-06-26 2008-01-03 Pfizer Products Inc. Composés hétéroaryliques tricycliques comme inhibiteurs de pde10
WO2009152825A1 (fr) 2008-06-20 2009-12-23 H. Lundbeck A/S Nouveau dérivés de phénylimidazole convenant comme inhibiteurs de l'enzyme pde10a
WO2010030027A1 (fr) * 2008-09-10 2010-03-18 Mitsubishi Tanabe Pharma Corporation Composés cycliques aromatiques azotés à 6 chaînons et leur utilisation
WO2012065612A1 (fr) * 2010-11-19 2012-05-24 H. Lundbeck A/S Dérivé d'imidazole en tant qu'inhibiteurs de l'enzyme pde10a

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING CO.
BERGE, S.M. ET AL., J. PHARM. SCI., vol. 66, 1977, pages 2
CANTIN ET AL., BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 17, 2007, pages 2869 - 2873
FUJISHIGE, K. ET AL., EUR J BIOCHEM., vol. 266, 1999, pages 1118 - 1127
GIAMPA ET AL., NEUROBIOLOGY OF DISEASE, vol. 34, no. 3, 2009, pages 450 - 456
GIAMPA ET AL., PLOS ONE, vol. 5, 2010, pages 10
HEBB ET AL., CURRENT OPINION IN PHARMACOLOGY, vol. 7, no. 1, 2007, pages 86 - 92
JANET S. DODD: "ACS Style Guide", 1997, article "The ACS Styleguide - A manual"
JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 14, no. 5, 1977, pages 889 - 92
JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO- ORGANIC CHEMISTRY, vol. 20, 1997, pages 2983 - 2988
JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1: ORGANIC AND BIO-ORGANIC CHEMISTRY, vol. 5, 1979, pages 1132 - 6
KEHLER, J. ET AL., EXPERT OPIN. THER. PATENTS, vol. 17, 2007, pages 147 - 158
KONRADI, C.; HECKERS, S., SOCIETY OF BIOLOGICAL PSYCHIATRY, vol. 50, 2001, pages 729 - 742
KOTERA, J. ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 261, 1999, pages 551 - 557
LOUGHNEY, K. ET AL., GENE, vol. 234, 1999, pages 109 - 117
NEVE, K. A. ET AL., JOURNAL OF RECEPTORS AND SIGNAL TRANSDUCTION, vol. 24, 2004, pages 165 - 205
ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 7, 2009, pages 128 - 134
RODEFER ET AL., EUR. J. NEUROSCI., vol. 4, 2005, pages 1070 - 1076
SEEGER, T. F. ET AL., BRAIN RESEARCH, vol. 985, 2003, pages 113 - 126
SEEGER, T.F. ET AL., BRAIN RESEARCH, vol. 985, 2003, pages 113 - 126
SODERLING, S. ET AL., PROC. NATL. ACAD. SCI., vol. 96, 1999, pages 7071 - 7076
VENKATESAN, A. ET AL., CHEMMEDCHEM, vol. 3, 2008, pages 1658 - 1661

Similar Documents

Publication Publication Date Title
EP2640731B1 (fr) Dérivé d'imidazole en tant qu'inhibiteurs de l'enzyme pde10a
CA2783727C (fr) Derives de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
EP2513106A1 (fr) Dérivés hétéroaromatiques d'aryltriazole en tant qu'inhibiteurs de l'enzyme pde10a
WO2013050527A1 (fr) Dérivés de quinazoline en tant qu'inhibiteurs de l'enzyme pde10a
US8796304B2 (en) Tricyclic imidazole compounds as PDE10 inhibitors
US9801878B2 (en) Quinoline derivatives as PDE10A enzyme inhibitors
WO2013045607A1 (fr) Dérivés tricycliques hétéroaromatiques liés à de la quinazoline pouvant être utilisés en tant qu'inhibiteurs de l'enzyme pde10a
HK1189593B (en) Imidazole derivatives as pde10a enzyme inhibitors
OA16430A (en) Imidazole derivatives as PDE10A ensyme inhibitors
WO2013127817A1 (fr) Dérivés d'imidazole comme inhibiteurs de l'enzyme pde10a
MX2013005592A (es) Derivados de imidazol como inhibidores de la enzima pde10a.
WO2013107856A1 (fr) Dérivés d'imidazole utilisés comme inhibiteurs d'enzymes pde10a
NZ626279B2 (en) Quinoline derivatives as pde10a enzyme inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12766314

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12766314

Country of ref document: EP

Kind code of ref document: A1